Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian Region Early Anistreplase Trial (GREAT).

OBJECTIVES This report presents the 5-year results of the Grampian Region Early Anistreplase Trial (GREAT) and quantifies the benefit of earlier thrombolysis in terms that are generally applicable. BACKGROUND Although it is accepted that the earlier thrombolytic therapy is given for acute myocardial infarction the greater the benefit, there are widely differing estimates of the magnitude of the time-related benefit of thrombolysis because of inappropriate trial design and analysis. METHODS In a previously reported randomized trial, anistreplase (30 U) was given intravenously either before hospital admission or in the hospital, at a median time of 105 and 240 min, respectively, after onset of symptoms. Intention to treat and multivariate analyses of the 5-year results were performed. RESULTS By 5 years, 41 (25%) of 163 patients had died in the prehospital treatment group compared with 53 (36%) of 148 in the hospital treatment group (log-rank test, p < 0.025). Delaying thrombolytic treatment by 1 h increases the hazard ratio of death by 20%, equivalent to the loss of 43/1,000 lives within the next 5 years (95% confidence interval 7 to 88, p = 0.012). Delaying thrombolytic treatment by 30 min reduces the average expectation of life by approximately 1 year. CONCLUSIONS The magnitude of the benefit from earlier thrombolysis is such that giving thrombolytic therapy to patients with acute myocardial infarction should be accorded the same degree of urgency as treatment of cardiac arrest. Policies should be developed for giving thrombolytic therapy on-site if practicable and by the first qualified person to see the patient.

[1]  W. Weaver,et al.  Time to thrombolytic treatment: factors affecting delay and their influence on outcome. , 1995, Journal of the American College of Cardiology.

[2]  Barr Jb,et al.  HOME OR AWAY? , 1964, Lancet.

[3]  J. Herlitz,et al.  Components of delay time in suspected acute myocardial infarction with particular emphasis on patient delay , 1990, Journal of internal medicine.

[4]  J. Rawles Problems in quantifying the benefit of earlier thrombolysis in acute myocardial infarction , 1995 .

[5]  E. Gang,et al.  Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. , 1989, The New England journal of medicine.

[6]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[7]  A. Davie Early thrombolytic treatment in acute myocardial infarction , 1996, The Lancet.

[8]  Gusto Angiographic Investigators The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.

[9]  E. Rose,et al.  Delay between the onset of symptoms of acute myocardial infarction and seeking medical assistance is influenced by left ventricular function at presentation. , 1995, British heart journal.

[10]  J. Rawles Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). , 1994, Journal of the American College of Cardiology.

[11]  T. Waterston FLUIDS FOR DIARRHŒA IN YOUNG CHILDREN , 1977, The Lancet.

[12]  D. Bonaduce,et al.  Effects of late administration of tissue-type plasminogen activator on left ventricular remodeling and function after myocardial infarction. , 1990, Journal of the American College of Cardiology.

[13]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[14]  R. Collins,et al.  Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. , 1997, The New England journal of medicine.

[15]  C. Fry,et al.  Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.

[16]  M. Simoons,et al.  Letter to the Editor. Effect of thrombolytic treatment delay on myocardial infarct size , 1992 .

[17]  J. Bourke,et al.  Reduction in incidence of inducible ventricular tachycardia after myocardial infarction by treatment with streptokinase during infarct evolution. , 1990, Journal of the American College of Cardiology.

[18]  Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group. , 1992, BMJ.

[19]  P. Kudenchuk,et al.  Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. , 1993, JAMA.

[20]  Eric Boersma,et al.  Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour , 1996, The Lancet.

[21]  J. Rawles,et al.  Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT) , 1996, BMJ.

[22]  R. Schröder,et al.  Prehospital thrombolysis: beneficial effects of very early treatment on infarct size and left ventricular function. , 1993, Journal of the American College of Cardiology.

[23]  S. Schmidt,et al.  The prehospital phase of acute myocardial infarction in the era of thrombolysis. , 1990, The American journal of cardiology.

[24]  P. Marino,et al.  Effect of streptokinase on left ventricular modeling and function after myocardial infarction: the GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico) Trial. , 1989, Journal of the American College of Cardiology.

[25]  R. Madhok,et al.  Duration of anticoagulation for deep-vein thrombosis and pulmonary embolism , 1992, The Lancet.

[26]  F. Sheehan,et al.  Time from onset of symptoms to thrombolytic therapy: A major determinant of myocardial salvage in patients with acute transmural infarction , 1987 .

[27]  J. Perry Prehospital-initiated vs hospital-initiated thrombolytic therapy for myocardial infarction. , 1994, JAMA.

[28]  J. Rawles,et al.  Impact of resuscitation and thrombolysis on mortality rate from acute myocardial infarction. , 1995, International journal of cardiology.

[29]  Aims Trial Study Group EFFECT OF INTRAVENOUS APSAC ON MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION: PRELIMINARY REPORT OF A PLACEBO-CONTROLLED CLINICAL TRIAL , 1988, The Lancet.

[30]  M. Simoons,et al.  Effect of thrombolytic treatment delay on myocardial infarct size , 1992, The Lancet.

[31]  J. Ritchie,et al.  Early versus late hospital arrival for acute myocardial infarction in the western Washington thrombolytic therapy trials. , 1989, The American journal of cardiology.

[32]  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.

[33]  M. Hori,et al.  Late Reperfusion for Acute Myocardial Infarction Limits the Dilatation of Left Ventricle Without the Reduction of Infarct Size , 1993, Circulation.

[34]  Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. , 1993, The New England journal of medicine.